Press Room - Sanofi US News

Menu

Media Room Menu

Month Year

Month Year

Sep 16, 2017

Sanofi and Regeneron Announce Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe Atopic Dermatitis

- Late-breaking oral abstract of Phase 3 CAFÉ study presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress -
Sep 14, 2017

Patient-Driven Dose Titration with Sanofi's Toujeo Improved Blood Glucose Control Without Increasing Hypoglycemia Risk in Real-Life Clinical Practice
- Photos 1
Sep 13, 2017

Daily Blood Glucose Measures in Phase 3 Clinical Trials Demonstrated Better Stability with Sanofi's Toujeo® vs. Insulin Glargine 100 Units/mL
Sep 12, 2017

Sanofi's Soliqua® 100/33 Provided Earlier Blood Sugar Control than Insulin Glargine 100 Units/mL

-- More adults reached HbA(1c) target at 8 and 12 weeks versus those receiving insulin glargine 100 Units/mL --
Sep 11, 2017

Sanofi and Regeneron Announce Positive Dupilumab Topline Results From Phase 3 Trial in Uncontrolled Persistent Asthma

- Investigational dupilumab reduced severe asthma attacks and improved lung function -

Show per page

Print
Email page
RSS

You are about to leave www.sanofi.us

If you wish to continue to this external website, click Proceed. It is provided for information only. Sanofi assumes no responsibility for the information presented on this website.